COVID-19 Antibody Blood Test (LTD905)
This test helps to identify a type of antibody called immunoglobulin G (IgG) that is the result of past or recent exposure to COVID-19 also known as the novel coronavirus.
Antibodies developed by the body in response to a viral infection may provide potential immunity against future infection. According to the U.S. Food and Drug Administration, COVID-19 antibody testing may indicate that the person has been exposed to the virus and developed antibodies against it, which may mean that person has at least some immunity to SARS-CoV-2.
This is not a test for an active infection. The COVID-19 antibody test should not be used as a sole basis to diagnose or exclude infection. This test is different from the COVID-19 PCR Swab test, which indicates if there is an active infection and that the virus is present.1
Who may benefit from this test:Anyone who knows or thinks they may have had COVID-19 and haven’t had any symptoms for the past 14 days and would like to know if they have developed antibodies.
Anyone who has not been diagnosed with COVID-19, this test may help determine if you may have been previously exposed to the virus. If you were exposed, it can check whether your body has produced antibodies.
For more information on this test, view the Patient Fact Sheet.
You may be able to submit the expenses associated with this testing to your Health Savings Account (HSA), Flexible Spending Account (FSA), Health Reimbursement Account (HRA), or similar account for reimbursement. Please check with your health account administrator.
- A false-negative result may occur in patients whose blood is drawn before a patient has produced enough IgG antibodies for the test to detect.
- Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
- Specimens from patients receiving therapeutic doses of Biotin (Vitamin H, B7, or B8) may interfere in immunoassays based on biotinylated reagents.
- Detection of IgG antibodies against SARS-CoV-2 at present is not yet established to determine long term immunity to the virus or to protect the patient against re-infection by the virus.
- The results obtained with this test should only be interpreted in conjunction with clinical findings, and the results from other laboratory tests and evaluations.
- This is especially important if the patient has had recent exposure to COVID-19, or clinical presentation indicates that COVID-19 is likely and diagnostic tests for other causes of illness (e.g., other respiratory illnesses) are negative.
- In this case, direct testing for the SARS-CoV-2 virus (e.g. PCR testing) should be considered.
- This test should not be used for screening of donated blood.
2 DiaSorin LIAISON® SARS-CoV-2 S1/S2 IgG [package insert]. Stillwater, MN: DiaSorin, April 2020.